Interview: Actelion CEO Aims To Drive 'Small Big Company' To Greater Growth In J&J
Executive Summary
Jane Griffiths tells Scrip that rather than reducing Actelion's reliance on PAH, there is still a lot to do in looking at different mechanisms and pathways for the disease and being under the J&J umbrella can only help.
You may also be interested in...
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.
Novartis Flies The Flag For US Despite More Job Cuts
It is still “a priority country,” the Switzerland-based giant tells Scrip, as around 240 jobs face the axe at Novartis’s development organizational unit across the Atlantic.